359 related articles for article (PubMed ID: 33063698)
21. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.
Holm K; Grabau D; Lövgren K; Aradottir S; Gruvberger-Saal S; Howlin J; Saal LH; Ethier SP; Bendahl PO; Stål O; Malmström P; Fernö M; Rydén L; Hegardt C; Borg Å; Ringnér M
Mol Oncol; 2012 Oct; 6(5):494-506. PubMed ID: 22766277
[TBL] [Abstract][Full Text] [Related]
22. Functional and therapeutic significance of EZH2 in urological cancers.
Liu X; Wu Q; Li L
Oncotarget; 2017 Jun; 8(23):38044-38055. PubMed ID: 28410242
[TBL] [Abstract][Full Text] [Related]
23. EZH2 is involved in silencing of WNT5A during epithelial-mesenchymal transition of colon cancer cell line.
Tao J; Shi L; Huang L; Shi H; Chen H; Wang Y; Wang T
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2211-2219. PubMed ID: 28748258
[TBL] [Abstract][Full Text] [Related]
24. HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer.
Mahara S; Lee PL; Feng M; Tergaonkar V; Chng WJ; Yu Q
Proc Natl Acad Sci U S A; 2016 Jun; 113(26):E3735-44. PubMed ID: 27303043
[TBL] [Abstract][Full Text] [Related]
25. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
Xu B; Konze KD; Jin J; Wang GG
Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
[TBL] [Abstract][Full Text] [Related]
26. Repression of E-cadherin by the polycomb group protein EZH2 in cancer.
Cao Q; Yu J; Dhanasekaran SM; Kim JH; Mani RS; Tomlins SA; Mehra R; Laxman B; Cao X; Yu J; Kleer CG; Varambally S; Chinnaiyan AM
Oncogene; 2008 Dec; 27(58):7274-84. PubMed ID: 18806826
[TBL] [Abstract][Full Text] [Related]
27. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.
Hoffmann MJ; Engers R; Florl AR; Otte AP; Muller M; Schulz WA
Cancer Biol Ther; 2007 Sep; 6(9):1403-12. PubMed ID: 18637271
[TBL] [Abstract][Full Text] [Related]
28. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
Au SL; Wong CC; Lee JM; Wong CM; Ng IO
PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
[TBL] [Abstract][Full Text] [Related]
29. The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers.
Bae WK; Yoo KH; Lee JS; Kim Y; Chung IJ; Park MH; Yoon JH; Furth PA; Hennighausen L
Mol Carcinog; 2015 Oct; 54(10):1172-80. PubMed ID: 25043748
[TBL] [Abstract][Full Text] [Related]
30. The noncanonical role of EZH2 in cancer.
Huang J; Gou H; Yao J; Yi K; Jin Z; Matsuoka M; Zhao T
Cancer Sci; 2021 Apr; 112(4):1376-1382. PubMed ID: 33615636
[TBL] [Abstract][Full Text] [Related]
31. PRC2-Mediated Epigenetic Suppression of Type I IFN-STAT2 Signaling Impairs Antitumor Immunity in Luminal Breast Cancer.
Hong J; Lee JH; Zhang Z; Wu Y; Yang M; Liao Y; de la Rosa R; Scheirer J; Pechacek D; Zhang N; Xu Z; Curiel T; Tan X; Huang TH; Xu K
Cancer Res; 2022 Dec; 82(24):4624-4640. PubMed ID: 36222718
[TBL] [Abstract][Full Text] [Related]
32. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.
Mu W; Starmer J; Yee D; Magnuson T
Epigenetics Chromatin; 2018 Dec; 11(1):71. PubMed ID: 30522506
[TBL] [Abstract][Full Text] [Related]
33. Beyond Expression: Role of Phosphorylated Residues of EZH2 in Lineage Plasticity in Prostate Cancer.
Nouruzi S; Tabrizian N; Zoubeidi A
Endocrinology; 2023 Feb; 164(4):. PubMed ID: 36718085
[TBL] [Abstract][Full Text] [Related]
34. EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer.
Chinaranagari S; Sharma P; Chaudhary J
Oncotarget; 2014 Aug; 5(16):7172-82. PubMed ID: 25115397
[TBL] [Abstract][Full Text] [Related]
35. The roles of EZH2 in cancer and its inhibitors.
Liu Y; Yang Q
Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376
[TBL] [Abstract][Full Text] [Related]
36. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer.
Chen H; Tu SW; Hsieh JT
J Biol Chem; 2005 Jun; 280(23):22437-44. PubMed ID: 15817459
[TBL] [Abstract][Full Text] [Related]
37. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
38. EZH2-Targeted Therapies in Cancer: Hype or a Reality.
Eich ML; Athar M; Ferguson JE; Varambally S
Cancer Res; 2020 Dec; 80(24):5449-5458. PubMed ID: 32978169
[TBL] [Abstract][Full Text] [Related]
39. EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition.
Romero P; Richart L; Aflaki S; Petitalot A; Burton M; Michaud A; Masliah-Planchon J; Kuhnowski F; Le Cam S; Baliñas-Gavira C; Méaudre C; Luscan A; Hamza A; Legoix P; Vincent-Salomon A; Wassef M; Holoch D; Margueron R
Nat Commun; 2024 Apr; 15(1):3452. PubMed ID: 38658543
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential.
Gan L; Yang Y; Li Q; Feng Y; Liu T; Guo W
Biomark Res; 2018; 6():10. PubMed ID: 29556394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
